Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC
October 11, 2019 08:00 ET
|
Alder BioPharmaceuticals, Inc.
Updated tender offer materials provide additional summary information regarding existing Lundbeck offer terms, including existing CVR terms, and additional information regarding existing Alder...
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
October 10, 2019 08:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of...
Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash
September 16, 2019 01:55 ET
|
Alder BioPharmaceuticals, Inc.
Enhances Lundbeck’s leading portfolio of brain disease therapies with Alder’s highly complementary intravenous (IV) therapy for migraine prevention, eptinezumabEptinezumab is an investigational...
Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society
September 05, 2019 16:01 ET
|
Alder BioPharmaceuticals, Inc.
- Data analyses from clinical trials to highlight eptinezumab’s efficacy and early, sustained quality of life improvements in the prevention of chronic migraine -- Preclinical data also to be...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2019 16:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences
August 28, 2019 16:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results
August 06, 2019 16:07 ET
|
Alder BioPharmaceuticals, Inc.
Data presented at American Academy of Neurology and American Headache Society Annual Meetings continue to support eptinezumab’s differentiated clinical profile and impact on quality of life measures ...
Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2019 16:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at Canaccord Genuity 39th Annual Growth Conference
August 01, 2019 08:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2019 Financial and Operating Results
July 30, 2019 16:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., July 30, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...